Aragen, a CRDMO, has launched the first phase of its biologics manufacturing facility in Bangalore, India. The $30 million project, executed by its subsidiary Aragen Biologics Pvt Ltd, has completed its first small-scale manufacturing project for a US-based organization, producing a novel anticancer monoclonal antibody.